相关实验视频
Updated: Aug 6, 2026
10:55
Rescue of Recombinant Newcastle Disease Virus from cDNA
Published on: October 11, 2013
19.3K
对表达IBV多表位组合纽卡斯尔病病毒的复合新生疫苗的安全评估
Lei Tan1, Xusheng Qiu1, Lujing Liang1
1Department of Avian Diseases, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Frontiers in microbiology
|August 15, 2024
概括
新的rNDV-IBV-T/B候选疫苗对家禽和哺乳动物是安全的,没有任何不良影响或传播. 这种仿真活体疫苗显示出控制纽卡斯尔病 (ND) 和传染性支气管炎 (IB) 的潜力.
科学领域:
- 兽医病毒学 兽医病毒学
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 纽卡斯尔病 (ND) 和传染性支气管炎 (IB) 是主要的家禽疾病,由纽卡斯尔病病毒 (NDV) 和传染性支气管炎病毒 (IBV) 引起.
- 目前针对ND和IB的疫苗面临局限性,包括不良的交叉保护和干扰问题,导致免疫失败.
- 之前开发的一种表达IBV表位体的重组NDV (rNDV-IBV-T/B) 显示出对这两种疾病具有有前途的免疫保护功效.
研究的目的:
- 评估转基因复合候选疫苗rNDV-IBV-T/B的生物安全性.
- 评估疫苗在目标家禽物种,非目标鸟类物种和哺乳动物中的安全性.
- 为了确定rNDV-IBV-T/B疫苗的水平和垂直传播潜力和环境安全.
主要方法:
- 用rNDV-IBV-T/B候选疫苗对一天大的小,小,小和ICR小鼠进行免疫接种.
- 监测临床症状,体重变化和尸检.
- 组织样本的组织病理分析和传播和环境生存的评估.
主要成果:
- 候选rNDV-IBV-T/B疫苗对,,或小鼠的生长没有产生不良影响.
- 组织病理学检查证实了疫苗在所有测试物种中的安全性.
- 没有观察到横向或垂直传播,疫苗在环境中无法存活.
结论:
- rNDV-IBV-T/B候选疫苗对,,和小鼠是安全的.
- 该疫苗没有显示传染能力,并且在环境上是安全的.
- rNDV-IBV-T/B是一种安全且有前途的仿真活疫苗,用于控制家禽的ND和IB.
相关概念视频
01:51Vaccinations
Overview
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...